Results
1 -
5 of
5The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia, Annals of Hematology Expanding the concepts of cancer metabolism, Experimental & Molecular Medicine Acute myeloid leukemiau2014current data from the 2017 American Society of Hematology meeting, memo - Magazine of European Medical Oncology Enasidenib: First Global Approval, Drugs Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia, Current Hematologic Malignancy Reports